Pro-inflammatory cytokines in the formation of the pre-metastatic niche

R Li, A Wen, J Lin - Cancers, 2020 - mdpi.com
Simple Summary The formation of the pre-metastatic niche, a favorable microenvironment in
an organ distant from a primary tumor, is critical for tumor metastasis. We review the role of a …

Syndecan-1 (CD138), carcinomas and EMT

JR Couchman - International journal of molecular sciences, 2021 - mdpi.com
Cell surface proteoglycans are known to be important regulators of many aspects of cell
behavior. The principal family of transmembrane proteoglycans is the syndecans, of which …

The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications

D Ogiya, J Liu, H Ohguchi, K Kurata… - Blood, The Journal …, 2020 - ashpublications.org
Anti-CD38 monoclonal antibody (MoAb) treatments including daratumumab (DARA) are
effective therapies for both newly diagnosed and relapsed multiple myeloma (MM). In this …

Belantamab mafodotin to treat multiple myeloma: a comprehensive review of disease, drug efficacy and side effects

G Lassiter, C Bergeron, R Guedry, J Cucarola… - Current …, 2021 - mdpi.com
Multiple myeloma (MM) is a hematologic malignancy characterized by excessive clonal
proliferation of plasma cells. The treatment of multiple myeloma presents a variety of unique …

Antibody-drug conjugate targets, drugs, and linkers

BA Teicher, J Morris - Current Cancer Drug Targets, 2022 - ingentaconnect.com
Antibody-drug conjugates offer the possibility of directing powerful cytotoxic agents to a
malignant tumor while sparing normal tissue. The challenge is to select an antibody target …

Antibody-drug conjugates for multiple myeloma

A McMillan, D Warcel, R Popat - Expert Opinion on Biological …, 2021 - Taylor & Francis
Introduction: Antibody-drug conjugates (ADC) are a new class of treatment for multiple
myeloma (MM) patients, delivering a potent cytotoxic agent directly to the myeloma cell. The …

[HTML][HTML] Development of a B-cell maturation antigen-specific T-cell antigen coupler receptor for multiple myeloma

K Bezverbnaya, D Moogk, D Cummings, CL Baker… - Cytotherapy, 2021 - Elsevier
Background aims T cells engineered with synthetic receptors have delivered powerful
therapeutic results for patients with relapsed/refractory hematologic malignancies. The …

Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma

A Suvannasankha, N Bahlis, S Trudel, K Weisel… - Cancer, 2024 - Wiley Online Library
Background Belantamab mafodotin (belamaf) has shown promising antimyeloma activity in
relapsed or refractory multiple myeloma (RRMM) as a single agent. It was hypothesized that …

Drug conjugated and bispecific antibodies for multiple myeloma: improving immunotherapies off the shelf

G Barilà, R Rizzi, R Zambello, P Musto - Pharmaceuticals, 2021 - mdpi.com
The impressive improvement of overall survival in multiple myeloma (MM) patients in the last
years has been mostly related to the availability of new classes of drugs with different …

Are autologous stem cell transplants still required to treat myeloma in the era of novel therapies? a review from the Chronic Malignancies Working Party of the EBMT

L Garderet, C Morris, M Beksac, G Gahrton… - Biology of Blood and …, 2020 - Elsevier
Melphalan at a myeloablative dose followed by autologous stem cell transplantation (ASCT)
remains the standard of care for transplant-eligible patients with myeloma. However …